MedTrace Logo

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

NCT06989671 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2025-08-27

No results posted yet for this study

Summary

This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.

Conditions

Interventions

DRUG

JMT101

JMT101 Q2W or Q3W, intravenous injection

DRUG

SYS6002

SYS6002 Q2W or Q3W, intravenous injection

DRUG

SG001

SG001 Q2W or Q3W, intravenous injection

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-30
Primary Completion
2027-12-30
Completion
2028-07-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06989671 on ClinicalTrials.gov